Cheng L, Hostetler K Y, Gardner M F, Avila C P, Bergeron-Lynn G, Keefe K S, Beadle J R, Wiley C A, Freeman W R
Shiley Eye Center, University of California-San Diego, La Jolla, USA.
J Ocul Pharmacol Ther. 1999 Aug;15(4):363-77. doi: 10.1089/jop.1999.15.363.
This study was conducted to evaluate the vitreous clarity and intraocular therapeutic index of three preparations ofthe carboxymethyl ester of 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA-O-Me), a long acting lipid derivative of foscarnet with potent anti-CMV activity. Twenty-six New Zealand white rabbits were intravitreally injected with one of three preparations of ODG-PFA-O-Me or control diluent. The vitreous clarity was graded after injection using indirect ophthalmoscopy and fundus photography. Drug intraocular toxicity was evaluated by electroretinography and by post-sacrifice tissue pathology using light and electron microscopy. Intravitreal injection of micellar ODG-PFA-O-Me showed variable local retinal toxicity and vitreal compound aggregates in eyes with the middle and high doses. The intraocular therapeutic index was lower than 465:1. Intravitreal injection of liposomal ODG-PFA-O-Me, either free acid or sodium salt, revealed clear vitreous for the 0.632 and 0.84 mM final intravitreal concentrations. No retinal toxicity was confirmed for the 1.12 mM final intravitreal concentration at the eight week observation following injection. The intraocular therapeutic index was between 585-1037:1. ODG-PFA-O-Me possesses better vitreous compatibility than ODG-PFA. Liposomal ODG-PFA-O-Me can be intravitreally injected with a resulting clear vitreous and high intraocular therapeutic index. Liposomal ODG-PFA-O-Me could be a long acting nontoxic intravitreous injectable drug for CMV retinitis.
本研究旨在评估1-O-十八烷基-sn-甘油-3-膦甲酸酯(ODG-PFA-O-Me)的三种制剂的玻璃体清晰度和眼内治疗指数,ODG-PFA-O-Me是一种具有强大抗巨细胞病毒(CMV)活性的长效脂质衍生物。26只新西兰白兔经玻璃体腔注射三种ODG-PFA-O-Me制剂之一或对照稀释剂。注射后使用间接检眼镜和眼底摄影对玻璃体清晰度进行分级。通过视网膜电图以及使用光学显微镜和电子显微镜的牺牲后组织病理学评估药物眼内毒性。玻璃体腔注射胶束状ODG-PFA-O-Me在中高剂量组眼中显示出可变的局部视网膜毒性和玻璃体化合物聚集体。眼内治疗指数低于465:1。玻璃体腔注射游离酸或钠盐形式的脂质体ODG-PFA-O-Me,对于最终玻璃体腔浓度为0.632和0.84 mM的情况,玻璃体保持清晰。在注射后八周的观察中,对于最终玻璃体腔浓度为1.12 mM的情况,未确认有视网膜毒性。眼内治疗指数在585 - 1037:1之间。ODG-PFA-O-Me比ODG-PFA具有更好的玻璃体相容性。脂质体ODG-PFA-O-Me可以经玻璃体腔注射,注射后玻璃体保持清晰且眼内治疗指数高。脂质体ODG-PFA-O-Me可能是一种用于治疗CMV视网膜炎的长效无毒玻璃体腔注射药物。